InMed Shares Update to Biosynthesis Program Development

- September 25th, 2017

InMed Pharmaceuticals shared an update to investors on the advancements of their proprietary technology for the microbial biosynthesis of cannabinoids.

InMed Pharmaceuticals (CSE:IN; OTCQB:IMLFF) shared an update to investors on the advancements of their proprietary technology for the microbial biosynthesis of cannabinoids.
As quoted in the press release:

InMed has successfully demonstrated that it can selectively produce all four “gateway” cannabinoids using genetically engineered microorganisms. These molecules can be functionalized further to produce any of the 90+ “downstream” cannabinoids found naturally in the cannabis plant. The company is actively employing this production chassis to synthesize compounds for its pharmaceutical research programs.
Eric A. Adams, President & CEO states, “Successful scale-up and commercialization of the biosynthesis process for cannabinoid production is a top priority for InMed.

Click here to read the full press release.

Get the latest Cannabis Investing stock information

Get the latest information about companies associated with Cannabis Investing Delivered directly to your inbox.

Cannabis Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

Leave a Reply

Your email address will not be published. Required fields are marked *